1. Department of Neurology, The Chaim Sheba Medical Center, Ramat Gan, Israel
2. Department of Internal Medicine A, The Chaim Sheba Medical Center, Ramat Gan, Israel
3. The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv Israel
Volume 35, Issue 1, March 2024
Sign in to download the Issue in PDF format.
672971798
Mediterr J Rheumatol 2020; 31(1):75-7
Article Links
Anti-MDA5 Positive Dermatomyositis Associated with Rapidly Progressive Interstitial Lung Disease and Correlation between Serum Ferritin Level and Treatment Response
Abstract
Clinically amyopathic dermatomyositis is an uncommon autoimmune disorder in the Middle East. The clinical picture of clinically amyopathic dermatomyositis is characterized mainly by pulmonary and dermatological manifestations. Occasionally muscle symptoms are observed as well. Serum anti-MDA5 autoantibody positivity is associated with rapidly progressive interstitial lung disease among clinically amyopathic dermatomyositis patients. Moreover, high serum ferritin level is correlated with poor prognosis and high mortality.
Herein we describe the case of an Israeli patient with rapidly progressive interstitial lung disease and without pathognomonic dermatological features who was diagnosed with anti-MDA5 positive clinically amyopathic dermatomyositis and did not survive despite immunomodulatory therapy followed by reduction in serum ferritin levels.
https://doi.org/10.31138/mjr.31.1.75
Article Submitted: 30 Nov 2019; Article Accepted: 15 Jan 2020; Published: 31 Mar 2020
This work is licensed under a Creative Commons Attribution 4.0 International License (CC-BY).
©Zohar DN, Seluk L, Yonath H, Shoenfeld Y, Kivity S.
Keywords: Anti-MDA5, clinically amyopathic dermatomyositis, interstitial lung disease, MSA, hyperferritinemia
